How to Help Your Patients Find Ongentys in Stock: A Provider's Guide

You've prescribed Ongentys (Opicapone) because it's the right medication for your patient's Parkinson's disease — once-daily dosing, effective COMT inhibition, and a favorable safety profile compared to Tolcapone. But then your patient calls back: their pharmacy doesn't carry it. Now what?

This guide walks you through practical, actionable steps to help your patients find and access Ongentys reliably. These are strategies you and your office staff can implement today.

Current Availability Landscape

Ongentys is not in a national shortage. It is available through the pharmaceutical distribution network and can be ordered by any licensed pharmacy. However, several factors make it harder for patients to find at the point of dispensing:

• Low stocking rates: Most chain pharmacies do not stock Ongentys routinely due to low prescription volume.
• No generic: Without generic competition, there is a single branded product in the market (patent expiry: March 2030).
• Prior authorization: Many insurance plans require PA, which can delay initial fills.
• Cost: The retail price ($645–$1,003/month) discourages pharmacies from carrying surplus inventory.

Why Patients Can't Find Ongentys

Understanding the specific barriers your patients face can help you target your interventions:

Pharmacy-Level Barriers

Chain pharmacies use automated inventory systems that stock based on demand signals. A drug with fewer than a handful of prescriptions per month at a given location may not meet the threshold for automatic stocking. Patients hear "we don't carry that" and assume it's unavailable everywhere.

Insurance-Level Barriers

Prior authorization requirements create the most common delay. When a PA hasn't been submitted or is pending, the pharmacy cannot dispense the medication. Some patients interpret this as a stock issue rather than an insurance issue.

Cost-Level Barriers

Even when a pharmacy can obtain Ongentys, a patient without adequate insurance coverage may balk at the $645+ cash price. Without awareness of the manufacturer savings program, patients may abandon the prescription entirely.

What Providers Can Do: 5 Steps

Step 1: Submit Prior Authorization Proactively

Don't wait for the pharmacy to reject the claim. If you know the patient's plan requires PA for Ongentys:

• Submit the PA at the time of prescribing, not after the patient goes to the pharmacy.
• Use CoverMyMeds (integrated with most EHR systems) for electronic PA submission. Neurocrine Biosciences partners with CoverMyMeds specifically for Ongentys.
• Include documentation of: Parkinson's disease diagnosis, current Levodopa/Carbidopa regimen, off episodes (frequency and impact), and any prior COMT inhibitor trial (if step therapy required).

Proactive PA submission can prevent the most frustrating patient experience: arriving at the pharmacy and being told they can't get their medication.

Step 2: Direct Patients to the Right Pharmacy

Use Medfinder for Providers to search for pharmacies near your patient that have Ongentys in stock. You can do this during the appointment or have your staff do it before the patient leaves, so they walk out with a specific pharmacy recommendation rather than a prescription and a prayer.

If no nearby pharmacies have stock, recommend:

• Mail-order pharmacy through the patient's insurance plan (often the most reliable option for ongoing prescriptions)
• Independent pharmacies that may be more willing to order specialty medications
• Hospital outpatient pharmacies at your own institution (if applicable)

Step 3: Enroll Patients in the Ongentys Savings Program

For commercially insured patients, the Ongentys Savings Program can reduce out-of-pocket costs to as little as $25 per prescription. This is applied automatically at most pharmacies once the patient is enrolled.

Key points about the program:

• Available to commercially insured patients only (not Medicare, Medicaid, or Tricare)
• Can be activated at the pharmacy — no separate enrollment card needed in many cases
• Details and enrollment at ongentys.com/support

For patients without commercial insurance or with government plans, explore other options like GoodRx (as low as $645), NeedyMeds, or RxAssist. See our provider's guide to saving on Ongentys for a complete breakdown.

Step 4: Leverage Neurocrine's INBRACE Support Program

Neurocrine Biosciences offers the INBRACE Support Program, which provides your practice with dedicated Reimbursement and Patient Access Managers (RPAMs). These field-based specialists can:

• Help navigate complex insurance situations
• Assist with prior authorization appeals
• Identify pharmacy solutions for patients having difficulty with access
• Provide information about copay and patient assistance programs

To connect with an RPAM, visit ongentyshcp.com/support or contact Neurocrine's HCP support line.

Step 5: Have a Backup Plan Ready

For patients who face persistent access challenges, it's helpful to have an alternative treatment plan ready. The most common alternatives include:

• Entacapone (generic Comtan): Available at virtually every pharmacy, ~$40-$50/month with coupons. Requires dosing with each Levodopa dose (up to 8x daily). Most practical for patients whose primary barrier is cost or immediate availability.
• Stalevo: Levodopa/Carbidopa/Entacapone combination tablet. Simplifies pill burden if patient is already on both drugs.
• Istradefylline (Nourianz): Once-daily adenosine A2A receptor antagonist. Different mechanism. May be considered if COMT inhibitors are not tolerated.
• Tolcapone (Tasmar): More potent COMT inhibitor, but requires liver function monitoring. Reserve for refractory cases.

For a full clinical comparison, see our alternatives to Ongentys guide.

Workflow Tips for Your Practice

Incorporating these steps into your standard workflow can prevent access problems before they start:

• At the point of prescribing: Check insurance formulary status and submit PA simultaneously with the e-prescription.
• Before the patient leaves: Verify pharmacy preference and confirm stock using Medfinder. Provide the savings program information.
• At follow-up: Ask about any access difficulties. If issues persist, escalate to Neurocrine's RPAM team or consider alternative therapy.
• For new starts: Consider providing a short bridge supply of Entacapone while PA for Ongentys is processed, if clinically appropriate.

Final Thoughts

Ongentys access challenges are real but solvable. The medication is not in shortage — the barriers are operational (pharmacy stocking, insurance, cost), and each has specific interventions. By proactively managing prior authorization, directing patients to the right pharmacies using Medfinder for Providers, enrolling patients in savings programs, and leveraging Neurocrine's support infrastructure, you can ensure your patients get the Parkinson's treatment you've prescribed.

For the broader supply and cost context, see our companion article: Ongentys Shortage: What Providers Need to Know in 2026.